ENTA — Enanta Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $339.02m
- $275.90m
- $65.32m
U.S. RESEARCH ROUNDUP-BP, Chipotle Mexican Grill, Hain Celestial Group
Enanta Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Enanta Pharmaceuticals Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2022 With Webcast And Conference Call Today At 430 P.M. Et
Enanta Pharmaceuticals Inc expected to post a loss of $1.59 a share - Earnings Preview
Enanta Pharma slips on downbeat Q4 revenue
U.S. RESEARCH ROUNDUP-Freshworks, PowerSchool Holdings, Upland Software
Enanta Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Enanta Pharmaceuticals Reports Financial Results For Fiscal Fourth Quarter And Full Year
Enanta Pharmaceuticals Inc expected to post a loss of $1.35 a share - Earnings Preview
Brief: Enanta Pharmaceuticals Initiates Phase 2 Trial Of Its Covid-19 Treatment
Brief: Enanta Pharmaceuticals Doses First Subject In A Phase 1 Clinical Study Of EDP-323, Its Novel, Oral L-Protein Inhibitor In Development For The Treatment Respiratory Syncytial Virus
Brief: Enanta Pharmaceuticals Initiates A Phase 2B Clinical Study Of EDP-938
Brief: Enanta Pharma Presents Preclinical Data For Its Respiratory Syncytial Virus And Human Metapneumovirus Programs At 12th International RSV Symposium
Brief: Enanta Pharmaceuticals Inc Entered Into Open Market Sale Agreement With Jefferies LLC For Offering Of Up To $100 Million Of Common Stock
U.S. RESEARCH ROUNDUP- Axon Enterprise, Berkeley Lights, Minerva Surgical
Enanta Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., As Senior Vice President And Chief Medical Officer
Brief: Enanta Pharmaceuticals Reports Q3 Loss Per Share $1.53
U.S. RESEARCH ROUNDUP-Abbvie, Centene, Charter Communications